Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab.

Sascha GerdesK AsadullahM HoffmannB KorgeD MortazawiS WegnerY PersonkeM GomezM Sticherling

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2022)

Guselkumab is efficacious and well tolerated regardless of previous biologic therapies, comorbidities or psoriasis manifestation in difficult-to-treat areas. No new safety signals were observed.

Keyphrases

rheumatoid arthritis
clinical trial
study protocol
atopic dermatitis
cross sectional
double blind